Red Blood Cell Antigen Genotyping, Fetal
Also known as: RBCGENO FE
Use
This test provides fetal genotyping for 35 red blood cell antigens and phenotypic variants to assess the risk for alloimmune hemolytic disease of the fetus and newborn (HDFN). It is used for identifying fetal antigen profiles to prevent hemolytic transfusion reactions and manage pregnancies at risk of HDFN due to maternal alloimmunization. The test results aid in determining the predicted fetal phenotypes based on the detected alleles and help assess potential health risks arising from antigen-antibody interactions.
Special Instructions
Not provided.
Limitations
The assay is limited in detecting only the targeted variants, and rare nucleotide changes that result in altered or partial antigen expression may not be detected. It does not assess RhD antigen presence or diagnose sickle cell disease. The presence of bloody amniotic fluid samples may lead to false-negative results due to maternal cell contamination. Patients who have undergone hematopoietic stem cell transplants may have inconclusive results.
New York Approved
Methodology
PCR-based (Fragment Analysis)
Biomarkers
LOINC Codes
- 59266-7 - Maternal Cell Contam Spec
- 66746-9 - Specimen type
- 31208-2 - Specimen source
- 50398-7 - Narrative diagnostic report-Imp
Result Turnaround Time
3-10 days
Related Documents
For more information, please review the documents below
Specimen
Amniotic Fluid
Volume
10 mL
Minimum Volume
5 mL
Container
Sterile container
Storage Instructions
Transport at critical temperature and must be received within 48 hours of shipment.
Causes for Rejection
Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 48 hours |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant